Evidence map›Paper›PMID 37384650›Full record

ArticlePloS one2023

RETRACTED: Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.

Mallory J DiVincenzo, Colin D Angell, Lorena P Suarez-Kelly, Casey Ren, Zoe Barricklow, Maribelle Moufawad, Paolo Fadda, Lianbo Yu, Floor J Backes, Kari Ring and 5 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Mallory J DiVincenzoThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.
Colin D AngellThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.
Lorena P Suarez-KellyDivision of Surgical Oncology, The Ohio State University, Columbus, OH, United States of America.
Casey RenThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.
Zoe BarricklowThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.ORCID 0000-0002-6041-8164
Maribelle MoufawadThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.ORCID 0000-0003-2383-1555
Paolo FaddaThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.
Lianbo YuThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.
Floor J BackesDivision of Gynecologic Oncology, The Ohio State University, Columbus, OH, United States of America.ORCID 0000-0002-9225-6913
Kari RingDivision of Gynecologic Oncology, University of Virginia, Charlottesville, VA, United States of America.
Anne MillsDepartment of Pathology, University of Virginia, Charlottesville, VA, United States of America.
Craig SlingluffDepartment of Surgery, University of Virginia, Charlottesville, VA, United States of America.
Catherine ChungThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.
Alejandro A GruDepartment of Pathology, University of Virginia, Charlottesville, VA, United States of America.
William E CarsonThe Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, United States of America.ORCID 0000-0001-7024-7533
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USUniversity of Virginia · USThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
UM1 Supplement for Early Therapeutic Trials with Phase 2 IntentUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON · 2014 to 2026
$19.3M
Medical Scientist Training Program - The Ohio State UniversityT32GM139784 · NIGMS · OHIO STATE UNIVERSITY · PI GINNY L BUMGARDNER, Rama K Mallampalli · 2021 to 2026
$5.7M
NCI NIH HHS P30 CA016058NCI NIH HHS UM1 CA186712NIGMS NIH HHS T32 GM139784
6 · The paper itself

Abstract

Melanomas from gynecologic sites (MOGS) are rare and have poor survival. MicroRNAs (miRs) regulate gene expression and are dysregulated in cancer. We hypothesized that MOGS would display unique miR and mRNA expression profiles. The miR and mRNA expression profile in RNA from formalin fixed, paraffin embedded vaginal melanomas (relative to vaginal mucosa) and vulvar melanomas (relative to cutaneous melanoma) were measured with the Nanostring Human miRNA assay and Tumor Signaling mRNA assay. Differential patterns of expression were identified for 21 miRs in vaginal and 47 miRs in vulvar melanoma (fold change >2, p<0.01). In vaginal melanoma, miR-145-5p (tumor suppressor targeting TLR4, NRAS) was downregulated and miR-106a-5p, miR-17-5p, miR-20b-5p (members of miR-17-92 cluster) were upregulated. In vulvar melanoma, known tumor suppressors miR-200b-3p and miR-200a-3p were downregulated, and miR-20a-5p and miR-19b-3p, from the miR-17-92 cluster, were upregulated. Pathway analysis showed an enrichment of "proteoglycans in cancer". Among differentially expressed mRNAs, topoisomerase IIα (TOP2A) was upregulated in both MOGS. Gene targets of dysregulated miRs were identified using publicly available databases and Pearson correlations. In vaginal melanoma, suppressor of cytokine signaling 3 (SOCS3) was downregulated, was a validated target of miR-19b-3p and miR-20a-5p and trended toward a significant inverse Pearson correlation with miR-19b-3p (p = 0.093). In vulvar melanoma, cyclin dependent kinase inhibitor 1A (CDKN1A) was downregulated, was the validated target of 22 upregulated miRs, and had a significant inverse Pearson correlation with miR-503-5p, miR-130a-3p, and miR-20a-5p (0.005 < p < 0.026). These findings support microRNAs as mediators of gene expression in MOGS.

Indexed as

MelanomaMicroRNAsSkin NeoplasmsVulvar NeoplasmsFemaleGenes, cdcHumansSuppressor of Cytokine Signaling ProteinsMicroRNAsMIRN145 microRNA, humanSuppressor of Cytokine Signaling Proteins

Identifiers

PMID37384650
PMCPMC10309992
OpenAlexW4382601094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.